Abstract:Background: Two commonly used forms of repetitive transcranial magnetic stimulation (rTMS) were recently shown to be equivalent for the treatment of treatment-resistant depression (TRD): high-frequency stimulation (10 Hz), a protocol that lasts between 19-38 minutes, and intermittent Theta-Burst Stimulation (iTBS), a protocol that can be delivered in just 3 minutes. Intermittent TBS offers significant advantages to patients and clinics and has thus become a default treatment in many clinics. However, it is unclear whether iTBS treatment offers the same benefits as standard 10 Hz rTMS for comorbid symptoms, such as post-traumatic-stress-disorder (PTSD). Methods: In this retrospective case series, we analyzed treatment outcomes in Veterans from the VA San Diego Healthcare system (VASDHS) who received 10 Hz (n = 47) or iTBS (n = 51) rTMS treatments for TRD between the dates of Jan 2017 to June 2022. We compared outcomes between these two stimulation protocols used between these dates on symptoms of depression (using changes in the patient health questionnaire-9, or PHQ-9) and PTSD (using changes in the PTSD Checklist for DSM-5, or PCL-5). We hypothesized that there would be no differences in treatment outcomes between 10 Hz and iTBS protocols for either depression (confirming prior RCT) or PTSD. Results: We found that both types of stimulation showed a clinically meaningful reduction in symptoms with no difference in outcomes based on the type of stimulation. The mean reduction on the PHQ-9 scale was 5.8 +/- 0.93 (p <0.001, n = 47) in Veterans receiving 10 Hz stimulation and 6.6 +/- 0.71 (p < 0.001, n = 51) in the Veterans receiving iTBS. There were no difference between stimulation protocols (p = 0.5). The mean reduction on the PCL-5 symptom scale was 8.1 +/- 2.1 in Veterans receiving 10 Hz stimulation (p <0.001, n =47) and -13.2 +/- 2.4 the Veterans receiving iTBS (p <0.001, n = 51). This difference was not significant (p=0.11) and had a small effect size (eta^2 = 0.026). Follow-up analyses restricting the sample in various ways did not meaningfully change these results. Conclusions: While limited by small sample size, non-blinded and pseudo-randomized assignment, our data suggests that iTBS can be expected to have similar if not slightly greater reductions in PTSD symptoms compared with 10 Hz stimulation. Our findings pave the way for further research trials to validate and optimize iTBS for PTSD symptoms.

Brain derived neurotrophic factor and treatment outcomes among veterans attending an intensive treatment program for posttraumatic stress disorder

Plasma Brain-Derived Neurotrophic Factor Levels in Patients Suffering from Post-Traumatic Stress Disorder.

Brain-Derived Neurotrophic Factor Delivered Intranasally Relieves Post-Traumatic Stress Disorder Symptoms Caused by a Single Prolonged Stress in Rats

Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer

Various BDNF administrations attenuate SPS-induced anxiety-like behaviors

Treatment Outcome-Related White Matter Differences in Veterans with Posttraumatic Stress Disorder

New Insights into Contradictory Changes in Brain-Derived Neurotrophic Factor (BDNF) in Rodent Models of Posttraumatic Stress Disorder (PTSD)

Plasma and Platelet Brain-Derived Neurotrophic Factor (BDNF) Levels in Bipolar Disorder Patients with Post-Traumatic Stress Disorder (PTSD) or in a Major Depressive Episode Compared to Healthy Controls

Predictive Blood Biomarkers of Targeted Intervention for Chronic Mental Health Symptoms following Traumatic Brain Injury

The Effectiveness of Using Neurofeedback in the Treatment of Post-Traumatic Stress Disorder: A Systematic Review

An intensive outpatient program with prolonged exposure for veterans with posttraumatic stress disorder: Retention, predictors, and patterns of change.

Using fMRI connectivity to define a treatment-resistant form of post-traumatic stress disorder

Neurofeedback for post-traumatic stress disorder: systematic review and meta-analysis of clinical and neurophysiological outcomes

Post-traumatic Stress Disorder Risk and Brain-Derived Neurotrophic Factor Val66Met.

Posttraumatic Stress Disorder is a Stronger Predictor of Long-Term Neurobehavioral Outcomes Than Traumatic Brain Injury Severity

Interaction of Brain-derived Neurotrophic Factor, Exercise, and Fear Extinction: Implications for Post-traumatic Stress Disorder

Longitudinal associations between early post-injury serum BDNF levels and the development of post-traumatic stress disorder over two years

Efficacy and acceptability of noninvasive brain stimulation for treating posttraumatic stress disorder symptoms: A network meta-analysis of randomized controlled trials

Posttraumatic growth-oriented peer-based training among U.S. veterans: evaluation of post-intervention and long-term follow-up outcomes

Effectiveness of theta burst versus high frequency repetitive transcranial magnetic stimulation in reducing symptoms of post-traumatic stress disorder in Veterans with depression: a retrospective case series.

Cognition and Ventral Attention Network Connectivity: Associations With Treatment Response in Posttraumatic Stress Disorder